Efficacy and Safety of Empagliflozin (BI 10773) in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 499 participants.

Also called NCT01210001

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 499 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01210001
  • EudraCT 2009-016154-40
Other papers using this trial's data
  • Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus Clinical therapeutics, 2015-08 DOI, PubMed 26138864

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
Not reported
Results first posted
(from the registry)
Countries
United States, Canada, Greece, India, Philippines, Thailand, Ukraine (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01210001. Randomized; double masking; primary purpose treatment. Start 2010-09 (registry gives no type); primary completion 2012-04 (actual). Results posted on 2014-06-17.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Empagliflozin (BI 10773) in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Placebo
Intervention (Drug)
BI 10773
Intervention (Drug)
Placebo
Intervention (Drug)
Placebo
Intervention (Drug)
Placebo
Intervention (Drug)
BI 10773
Lead sponsor
Boehringer Ingelheim (class: industry)
Collaborator
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct01210001
Content hash
68b3f0fbd50f867742995720de83996966cdfe1da0480c3912d3b31b8f428668